# Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

> **NCT00920140** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 97 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** GSK1120212
- **DRUG:** GSK1120212

## Key facts

- **NCT ID:** NCT00920140
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2014-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920140, "Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias". Retrieved via AI Analytics 2026-06-19 from https://api.ai-analytics.org/clinical/NCT00920140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*